ClinicalTrials.gg
RecruitingNCT06413953Updated Jul 29, 2026

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

A Phase 1 interventional study of TQB3107 Tablets in Advanced Cancers, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

TQB3107 is an target inhibitor that binds to target to induce apoptosis and inhibits the proliferation of a variety of tumor cells. This is a clinical study to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).

02

Conditions studied

  • Advanced Cancers
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years ≤ age≤ 75 years (calculated from the date of signing the ); Score 0\~1 point, estimated survival ≥ 3 months;
  • Advanced malignant tumor;
  • The major organs are functioning well;
  • Negative serum pregnancy test within 7 days prior to the first dose and must be a non-lactating subject, female and male subjects of should agree to use throughout the study and for 6 months after the study ends;
  • Subjects voluntarily participated in this study, signing the informed consent form and demonstrating good compliance.

Exclusion criteria

Exclusion Criteria:

  • Hematologic has or is suspected to involve the central nervous system, or primary central nervous system lymphoma;
  • Received any anti-cancer therapy such as major surgery, chemotherapy and/or radiotherapy, immunotherapy, or targeted therapy within 4 weeks prior to the first dose;
  • Combined with severe or not well-controlled diseases, which the investigator judges to be at greater risk of entering this study;
  • Those with a history of drug addiction or substance abuse;
  • According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered to be unsuitable for enrollment for other reasons.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    TQB3107 tablets

    Dosing regimen 1 (20/28): 28 days per cycle (4 weeks), the medication is administered once daily for 5 consecutive days per week, followed by a 2-day break. The initial dose is a single fasting dose of C0, with a subsequent 7-day observation period. Dosing regimen 2 (12/28): every 28 days per cycle, with intermittent dosing.

    Drug: TQB3107 Tablets

Interventions

  • DrugTQB3107 Tablets

    TQB3107 Tablets is a selective target inhibitor.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    DLT refers to toxicities that are associated with the drug and occur from the first medication administration to the end of the first treatment cycle, as defined by the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 toxicity assessment criteria.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Maximum tolerated dose (MTD)

    MTD is defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  3. Phase II Recommended Dose (RP2D)

    The recommended dose, determined after initial dose escalation and toxicity assessment, it is used to further evaluate the efficacy and safety of the drug.

    Time frame: Baseline up to 24 months

Secondary outcomes

  1. Elimination half-life (t1/2)

    The time it takes for the concentration of the drug in the plasma to be reduced by 50%.

    Time frame: Cycle 0 Day 1: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24, 48 hours. Cycle 1 Day 1, 5, 12: 24 hours post-dose only. Cycle 1 Day 26: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24 hours.

  2. Time to Peak (Tmax)

    The time it takes to reach peak concentrations after administration.

    Time frame: Cycle 0 Day 1: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24, 48 hours. Cycle 1 Day 1, 5, 12: 24 hours post-dose only. Cycle 1 Day 26: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24 hours.

  3. Peak Concentration (Cmax)

    Maximum plasma concentration of drug.

    Time frame: Cycle 0 Day 1: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24, 48 hours. Cycle 1 Day 1, 5, 12: 24 hours post-dose only. Cycle 1 Day 26: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24 hours.

  4. Area under the plasma concentration-time curve (AUC0-last)

    The area enclosed by the plasma concentration curve against the timeline.

    Time frame: Cycle 0 Day 1: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24, 48 hours. Cycle 1 Day 1, 5, 12: 24 hours post-dose only. Cycle 1 Day 26: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24 hours.

  5. Steady-state peak concentration (Css-max)

    The highest plasma drug concentration that occurs after stabilization.

    Time frame: Cycle 0 Day 1: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24, 48 hours. Cycle 1 Day 1, 5, 12: 24 hours post-dose only. Cycle 1 Day 26: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24 hours.

  6. Steady-state trough concentration (Css-min)

    Minimum plasma drug concentration during dosing.

    Time frame: Cycle 0 Day 1: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24, 48 hours. Cycle 1 Day 1, 5, 12: 24 hours post-dose only. Cycle 1 Day 26: pre-dose ≤ 30 minutes; post-dose: 15, 30 minutes, 1, 2, 3, 4, 8, 12, 24 hours.

  7. Objective Response Rate (ORR)

    The percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.

    Time frame: UP to 3 years

  8. Disease Control Rate (DCR)

    Proportion of patients whose tumors achieve remission (PR+CR) and stable disease (SD) after treatment and can maintain the minimum timeframe required according to accepted response evaluation criteria (e.g., RECIST version 1.1 for solid tumors).

    Time frame: UP to 3 years

  9. Duration of Response (DOR)

    The time from first documented response to documented disease progression.

    Time frame: UP to 3 years

  10. Progression-free survival (PFS)

    The time from the start of treatment to tumor progression or death from any cause, whichever occurs first.

    Time frame: UP to 3 years

  11. Overall Survival (OS)

    The time from the start of treatment to death from any cause.

    Time frame: UP to 3 years

07

Study locations

11 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Oct 2026, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2024
First posted
May 14, 2024
StartActual
Jun 27, 2024
Primary completionEst.
Oct 2026
CompletionEst.
Jun 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06413953
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Jun 27, 2024
Primary completion
Oct 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

ZhiMing Li, Doctor
Contact
lzmsysu@163.com
13719189172
HuiLai Zhang, Doctor
Contact
zhlwgq@126.com
18622221228

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion